Drugs / CRMA-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07200193 | Dec 2025 → Dec 2032 expected | chronic hepatitis B virus infection | nChroma Bio | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-16 | nChroma Bio | Regulatory nChroma Bio Receives Authorization of Clinical Trial Application to Initiate First-in-Human Study for Epigenetic Silencer CRMA 1001 for the Treatment of Chronic Hepatitis B nchromabio.com ↗
This regulatory clearance marks a defining milestone for nChroma and for patients affected by chronic HBV, |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRMA-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07200193 ↗ |
| Modality | Other / unclassified | “CRMA-1001 is an epigenetic gene therapy delivered via intravenous (IV) infusion.” NCT07200193 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT07200193 ↗ |